-
Guangdong Provincial Food and Drug Administration: Sufficient supply of drugs, no need to blindly "stock up on drugs
Time of Update: 2023-01-01
According to the "Guangdong Drug Administration" public account news on December 3, recently, the "new crown medicine order" chart, "new crown drug hoarding list" and so on have gone viral on social platforms, and many citizens and friends have also begun to follow the trend of hoarding medicine, is it really necessary?
-
The first pharmaceutical company on the Science and Technology Innovation Board held a performance briefing, and it has been listed for less than three months
Time of Update: 2022-05-01
On March 1, it was reported that two companies including Dizhe Medicine took the lead and opened the 2021 performance briefing on the Science and Technology Innovation Board . At present, the number
-
CXO enters the performance release period, and a large number of companies have outstanding performance
Time of Update: 2022-04-21
As of March 28, among the more than ten CXO companies listed in China, 6 companies including WuXi AppTec, WuXi Biologics, Pharmaron, Zhaoyan New Drug, Medicilon, and Proton have released their 2021 annual reports.
-
Enthusiasm for the research and development of innovative traditional Chinese medicine drugs is high, and a large number of enterprises will benefit
Time of Update: 2022-04-20
At present, in addition to the continuous approval of new traditional Chinese medicines, a large number of pharmaceutical companies are enthusiastic about innovation, and many listed traditional Chinese medicine companies have indicated that they will increase their research and development efforts and investment in new traditional Chinese medicines in the future .
-
Local pharmaceutical companies launch innovative drugs overseas, and welcome new progress
Time of Update: 2022-04-17
Recently, BeiGene announced that the Marketing Authorization Application (MAA) of its self-developed PD-1 monoclonal antibody Baizean® (generic name: Tislelizumab injection) was officially accepted by the European Medicines Agency (EMA).
-
Brief Analysis of the Progress of Consistency Evaluation of Generic Drugs in 2021
Time of Update: 2022-01-25
CPM New Drug Development Monitoring Database The content of the first reviewed varieties decreased In 2021, the cumulative number of over-evaluated drugs increased from 426 at the beginning of the year to 652 at the end of the year, that is, among the nearly 2,000 over-evaluated generic drug approvals approved this year, 226 were first over-evaluated .
-
Announcement of the State Food and Drug Administration on Revising the Instructions for Benzbromarone Oral Preparations (No. 150 of 2020
Time of Update: 2021-07-07
In order to further protect the safety of public medication, the State Drug Administration has decided to revise the instructions for benzbromarone oral preparations .
Attachment: Requirements for the revision of the instructions for benzbromarone oral preparations State Food and Drug Administration December 29, 2020
-
Xianju Pharmaceutical's drospirenone and ethinylestradiol tablets (Ⅱ) domestic production drug registration application approved
Time of Update: 2021-05-21
On May 12, Xianju Pharmaceutical issued an announcement stating that it had recently received a notification of acceptance of registration for domestic production of drospirenone and ethinyl estradiol tablets (II) issued by the State Drug Administration.
The reference preparation is the imported original product drospirenone and ethinyl estradiol tablets (II) (trade name: Yousiyue®), which is marketed in China.
-
AI discovers 15 potential treatments for Alzheimer's disease and 5 JAK inhibitors on the list
Time of Update: 2021-03-22
Patients with Alzheimer's disease (AD) urgently need effective new therapies, but the effects of many drugs under investigation in clinical trials are not ideal.
They found that 15 drugs that have been approved by the FDA have the potential to treat AD, and 5 of them are JAK kinase inhibitors.
-
China NMPA accepts application for clinical trial of PD-1/TGF-β bifunctional fusion protein
Time of Update: 2021-03-19
(Junshi Biosciences) announced that its clinical trial application PD-1 / TGF-β bifunctional fusion protein injection JS201 (JS201) has been China's State Drug Administration accepted Bureau (NMPA).
Its anti-PCSK9 monoclonal antibody is the first clinical trial approved by NMPA in China.
-
The world's first declared clinical BTK-PROTAC has arrived
Time of Update: 2021-03-04
HSK29116 is an oral PROTAC small molecule anti-tumor drug that selectively blocks BTK kinase activity and interferes with B cell development by regulating signaling path paths to control the progression of various B-cell malignancies.
HSK29116 is the world's first declared clinical oral BTK-PROTAC small molecule anti-tumor drug based on Hesco's PROTAC research and development platform.
-
A new version of the drug catalog is about to be released Children's drug research and development into the fast lane
Time of Update: 2021-02-20
According to the 2019 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments) released by the National Health Insurance Administration, a new version of the drug catalogue will be issued in June this year, with children's medications named as priority for transfer to medicines.
-
The company was founded as a strategic partnership with the world's leading biopharmaceutical company to deliver innovative drugs to patients in Asia and around the world Press release
Time of Update: 2020-12-26
announced a joint venture with Allogene Overland Biopharm on December 15, 2020, focusing on the development, production and commercialization of AlloCAR T therapies for patients in Greater China, Korea and Singapore.
-
Target C3 nephropathy (C3G) the underlying cause! Novaral's powerful selective factor B inhibitor iptacopan significantly reduces proteinuria levels
Time of Update: 2020-11-11
() Original origin: Novartis presents offers interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
-
Chengdu Bett took the "hepatitis B drug" the first imitation of 20 new products on the road
Time of Update: 2020-10-31
to date, Chengdu Bett Pharmaceuticals has 20 varieties (29 acceptance numbers) of generic drugs reported in the new classification reviewed and will be treated as if they had passed a consistency evaluation after being approved for production.
